A novel angiogenesis inhibitor, XXXX , in encapsulating peritoneal sclerosis.

@entity1 @entity32 @entity82 @entity2240 @entity2976 @entity657 @entity6667 @entity35 @entity669 @entity1068 @entity413 @entity5164
INTRODUCTION: @entity2976 ( @entity2976 ) is characterized by neoangiogenesis and @entity82 . Increased @entity32 is the leading cause of @entity2976 . In turn, neoangiogenesis is both a consequence of and contributor to @entity32 . The effects of @entity2240 , a multitargeted receptor @entity669 kinase inhibitor, have been postulated in various antiangiogenesis, antiinflammatory and antifibrotic processes both in vitro and in vivo. This novel angiogenesis inhibitor, Sutent ( @entity2240 ), was investigated in our @entity35 @entity2976 model. MATERIALS AND METHODS: Forty nonuremic @entity35 albino @entity35 were divided into 4 groups as follows: 2-mL isotonic saline intraperitoneally (i.p.) daily, for 3 weeks (control group); daily 2 ml/200 g injection i.p. of @entity5164 (0.1%) and @entity1068 (15%) dissolved in saline, 3 weeks (CG group); CG + additional 3 weeks without any treatment, total 6 weeks (resting group); and CG + additional 3 weeks 1 mg/kg daily Sutent (SUT) in drinking water, total 6 weeks (SUT group). At the end of the study, 1-hour PET was performed. Functional parameters and morphological changes of peritoneum with dialysate cytokine levels were examined. RESULTS: SUT renewed ultrafiltration failure, D1/D0 @entity413 levels and dialysate protein loss. Peritoneal thickness, white blood cell count and @entity32 of peritoneum were also decreased with SUT treatment. SUT significantly improved overexpression of @entity657 and @entity6667 ( @entity6667 ) levels as compared with resting group. CONCLUSION: In conclusion, SUT might preserve membrane viability even at lower dosages. Although this is an experimental study, we believe that SUT after controlled trials may be a therapeutic agent for long-term peritoneal dialysis @entity1 .
